Form 4 for DNLI Denali Therapeutics Inc.
Accepted 2024-08-22 00:00:00 ET · period of report 2024-08-20 · accession 0001714899-24-000196 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-08-22 | 2024-08-20 | DNLI | Krognes Steve E. | Dir | S - Sale | $23.79 | -1,727 | 32.7K | -5% | -$41.1K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-08-20 | S | D | 1,727 | $23.79 | 32,677 | D | — | — | (F2) The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $23.75 to $23.79 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. (F3) Includes 13,467 Unvested RSUs. |